Ovarian Cancer News and Research RSS Feed - Ovarian Cancer News and Research Twitter

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
New combination therapy improves survival in patients with advanced ovarian cancer

New combination therapy improves survival in patients with advanced ovarian cancer

Epithelial ovarian cancer is the most lethal cancer of the female reproductive organs, with more than 200,000 new cases and more than 125,000 deaths each year worldwide. [More]
TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune, Inc., is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida, a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers. [More]
Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy - and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal European Urology, points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients. [More]
Chemotherapy drug combined with cancer-killing virus may treat recurrent ovarian cancer

Chemotherapy drug combined with cancer-killing virus may treat recurrent ovarian cancer

In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent. [More]
U of G research may lead to novel treatment approaches for late-stage ovarian cancer

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

In a potential breakthrough against ovarian cancer, University of Guelph researchers have discovered how to both shrink tumours and improve drug delivery, allowing for lower doses of chemotherapy and reducing side effects. [More]
RPCI researchers identify two novel candidate prognostic markers for ovarian cancer

RPCI researchers identify two novel candidate prognostic markers for ovarian cancer

Cancer researchers at Roswell Park Cancer Institute have identified two independent classes of novel candidate prognostic markers for ovarian cancer, advancing efforts to develop targeted therapies for the disease. The findings resulted from two separate studies published in the peer-reviewed journal PLoS ONE and based on data from The Cancer Genome Atlas (TCGA), the world's largest public database on gene expression in different tumor types. [More]
Cigarette smoking increases risk of developing second smoking-associated cancer

Cigarette smoking increases risk of developing second smoking-associated cancer

Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers. [More]
Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania. [More]
Dr. Grace Campbell receives RNF Fellow Research Grant Award

Dr. Grace Campbell receives RNF Fellow Research Grant Award

The Rehabilitation Nursing Foundation (RNF) presents Dr. Grace Campbell, PhD BSN RN CRRN MSW, with the RNF Fellow Research Grant Award. RNF offers $30,000 in the form of multiple grants for research projects that address the clinical practice, educational or administrative dimensions of rehabilitation nursing. Dr. Campbell received her award at the ARN 40th Annual Educational Conference, October 29 - November 1, 2014 in Anaheim, CA. [More]
People with lactose intolerance at lower risk of suffering from certain cancers

People with lactose intolerance at lower risk of suffering from certain cancers

People with lactose intolerance are at lower risk of suffering from lung, breast and ovarian cancers, according to a new study by researchers at Lund University and Region Skåne in Sweden. [More]
CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs. [More]
Moffitt researcher uncovers new approach to treat cancer

Moffitt researcher uncovers new approach to treat cancer

The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs. [More]
Dietary flavonoids decrease risk of developing epithelial ovarian cancer

Dietary flavonoids decrease risk of developing epithelial ovarian cancer

Tea and citrus fruits and juices are associated with a lower risk of developing ovarian cancer, according to new research from the University of East Anglia. [More]
UT Southwestern receives CPRIT grant to expand genetic screening services in North Texas

UT Southwestern receives CPRIT grant to expand genetic screening services in North Texas

Genetic screening services for rural and underserved populations will expand from six to 22 counties in North Texas under a $1.5 million grant from the Cancer Prevention and Research Institute of Texas to UT Southwestern Medical Center. [More]
Despite rise in use of hospice care, hospital-based services increase for ovarian cancer patients

Despite rise in use of hospice care, hospital-based services increase for ovarian cancer patients

There have been widespread efforts to improve the quality of life of terminally ill patients. As more patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. [More]
Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer. [More]
Half-day educational program can help educate women on side effects of cancer prevention surgery

Half-day educational program can help educate women on side effects of cancer prevention surgery

More women are having ovary-removing surgery as a cancer prevention measure, but many are often unaware of sexual or psychological side effects of the procedure. A new study by researchers at Dana-Farber Cancer Institute shows a half-day educational program can help successfully deal with these issues by educating women on how to address them. [More]
Researchers develop ADNEX test to help doctors diagnose ovarian cancer, choose best treatment

Researchers develop ADNEX test to help doctors diagnose ovarian cancer, choose best treatment

Researchers have devised a new test to help doctors diagnose ovarian tumours and choose the most appropriate treatment. [More]
Penn Medicine announces recipients of new Basser External Research Grant Program

Penn Medicine announces recipients of new Basser External Research Grant Program

The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration. [More]
Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

For benign gynecologic conditions, robot-assisted surgery involves more complications during surgery and may be significantly more expensive than conventional laparoscopic surgery, according to a study by researchers at Columbia University Medical Center. [More]